Rapid Production of Cells for Screening Voltage-Gated Ion Channels in Automated Electrophysiology Assays Using the MaxCyte® STX™ Scalable Transfection System
Comprising a family with hundreds of members, ion channels represent one of the largest classes of drug targets. Recent advances in automated electrophysiology instrumentation have led to the routine implementation of high throughput assays for screening ion channel modulators.
Read MoreRapid and Stable Protein Production with Consistent Quality to Accelerate Biotherapeutic Development Regulatory Sciences for Biologics & Vaccines
Rapid recombinant protein production is one of the key elements for drug development success.
Read MoreHybrid ssDNA repair templates enable high yield genome engineering in primary cells for disease modeling and cell therapy manufacturing
Here a GMP-compatible method for fully non-viral CAR-T cell manufacturing was developed, demonstrating knock-in efficiencies of 46-62% and generating yields of >1.5 x 109 CAR+ T cells, well above current doses for adoptive cellular therapies.
Read MoreImmunotherapy of Autologous Tumor Lysate-loaded Dendritic Cell Vaccines by a Closed-flow Electroporation System for Solid Tumors
Dendritic cell (DC)-based vaccines with the use of various antigen loading methods have been developed for cancer immunotherapy.
Read MoreLarge Volume Flow Electroporation of mRNA: Clinical Scale Process
Genetic modification for enhancing cellular function has been continuously pursued for fighting diseases. Messenger RNA (mRNA) transfection is found to be a promising solution in modifying hematopoietic and immune cells for therapeutic purpose. We have developed a flow electroporation-based system for large volume electroporation of cells with various molecules, including mRNA.
Read MoreLiterature Review: CHO versus HEK Cell Glycosylation
Choosing a host system for the expression of recombinant proteins should be carefully evaluated prior to the initiation of any biotherapetuic development programs.
Read MoreHigh Yield Transient and Stable Protein Production Using CHO Cell Line of Choice: From Transient Transfection to CHO Genome Modification and Cell Line Development
One aspect of lowering costs and reducing attrition rates during biotherapeutic development is the ability to work in the same host cell from early-stage discovery through biomanufacturing.
Read MoreHigh-level Production of Antibody Derivatives and Alternative Antibody Isotypes Using Scalable Cell Engineering
Antibody derivatives, such as bispecifics and Fc fragments, as well as alternative, non-IgG1 antibody isotypes represent promising classes of cancer immunotherapy. Their expression, however, can be challenging, complicating preclinical evaluation which can require significant amounts of recombinant protein.
Read MoreExPERT STx
The ExPERT STx electroporation technology is capable of high-performance delivery of virtually any molecule, into any cell, at any scale with the unique ability to transfect primary cells, stem cells and cell lines with minimal disturbance resulting in transfection efficiencies routinely ≥90%.
Read MoreExpression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method
Natural killer (NK) cells hold promise for cancer therapy. NK cytotoxicity can be enhanced by expression of chimeric antigen receptors that re-direct specificity toward target cells by engaging cell surface molecules expressed on target cells. We developed a regulatory-compliant, scalable non-viral approach to engineer NK cells to be target-specific based on transfection of mRNA encoding chimeric receptors.
Read More
